Abstract
Thursday, November 12, 2020
Workshop 1: Novel Software
Panel 1: Artificial Intelligence
8:00
Wayne Bequette, PhD
Rensselaer Polytechnic Institute, Troy, New York, USA
Piotr Ladyzynski, PhD
Nalecz Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences, Warsaw, Poland
8:05
Boris Kovatchev, PhD
University of Virginia, Charlottesville, Virginia, USA
8:20
Moshe Phillip, MD
National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel
8:35
Peter Jacobs, PhD
Oregon Health and Science University, Portland, Oregon, USA
8:50
Mercedes Rigla, MD, PhD
Parc Taulí Sabadell University Hospital, Barcelona, Spain
9:05
9:30
Panel 2: Digital Health and Telemedicine
9:55
David Ahn, MD
Mary & Dick Allen Diabetes Center at Hoag, Newport Beach, California, USA
Jennifer Raymond, MD, MCR
University of Southern California, Los Angeles, California, USA
10:00
Aaron Neinstein, MD
UCSF, San Francisco, California, USA
10:15
Rolf Hinzmann, MD, PhD
Roche Diagnostics, Manheim, Germany
10:30
Elizabeth Holt, MD, FACE
Lifescan, Wayne, Pennsylvania, USA
10:45
Mark Clements, MD, PhD
Glooko, Mountain View, California, USA
11:00
Ronald Dixon, MD
Remedy, Austin, Texas, USA
11:15
11:40
Workshop 2: Glucose Monitoring
Panel 1: Noninvasive
12:40
Gerard Coté, PhD
Texas A & M University, College Station, Texas, USA
Brian Frier, BSc (Hons), MD, FRCP(Edin), FRCP(Glas) University of Edinburgh, Edinburgh, Scotland
12:45
Mark Arnold, PhD
University of Iowa, Iowa City, Iowa, USA
13:00
Michael Heise, PhD
South-Westphalia University of Applied Science, Iserlohn, Germany
13:15
Kåre Birkeland, MD
Aker University Hospital, Oslo, Norway
13:30
Christopher Wilson, PhD
Listerdale Lifescience BV, Nijmegen, Netherlands
13:45
Wei Gao, PhD
California Institute of Technology, Pasadena, California, USA
14:00
14:20
Panel 2: Novel Technologies in CGMs
14:45
Jennifer Sherr, MD, PhD
Yale University, New Haven, Connecticut, USA
Hubert Vesper, PhD
Centers for Disease Control and Prevention, Atlanta, Georgia, USA
14:50
Faz Chowdhury, PhD
CEO, Nemaura Medical, Loughborough, UK
15:05
Francine Kaufman, MD
Senseonics, Germantown, Maryland, USA
Andreas Stuhr, MD, MBA
Ascensia Diabetes Care, Parsippany, New Jersey, USA
15:20
Mihailo Rebec, PhD
Waveform Technologies, Wilsonville, Oregon, USA
15:35
Marc Taub, PhD
Abbott Diabetes Care, Alameda, California, USA
15:50
Peter Simpson, MS
DexCom, Inc., San Diego, California, USA
16:05
Akhil Srinivasan, PhD
Medtronic Diabetes, Washington DC, USA
16:20
16:45
Friday, November 13, 2020
8:00
David Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE
Mills-Peninsula Medical Center, San Mateo, California, USA
8:05
Timothy Stenzel, MD, PhD
Director, Office of In Vitro Diagnostics and Radiological Health at the FDA, Silver Spring, Maryland, USA
Session 1: What Are the Best Metrics for Expressing Glycemia in CGM?
8:30
Guillermo Arreaza-Rubin, MD
NIDDK/NIH, Bethesda, Maryland, USA
Jessica Castle, MD
Oregon Health Sciences University, Portland, Oregon, USA
8:30
Lutz Heinemann, PhD
Science Consulting in Diabetes GmbH, Neuss, Germany
8:40
David Rodbard, MD
Biomedical Informatics Consultants LLC, Potomac, Maryland, USA
8:50
Boris Kovatchev, PhD
University of Virginia, Charlottesville, Virginia, USA
9:00
Richard Bergenstal, MD
International Diabetes Center, Minneapolis, Minnesota, USA
9:10
Session 2: What Role Does BGM Have in the Future?
9:40
Robert Gabbay, MD, PhD
Chief Scientific and Medical Officer, American Diabetes Association, Arlington, Virginia, USA
John Pickup, MA, BM, DPhil, DSc, FRCPath
King’s College London, London, United Kingdom
9:45
Robert Schumm, MBA
President, Ascensia Diabetes Care, Basel, Switzerland
9:55
Richard Bergenstal, MD
International Diabetes Center, Minneapolis, Minnesota, USA
10:05
Steven Edelman, MD
Veterans Affairs Medical Center, UC San Diego, La Jolla, California, USA
10:15
Andreas Pfützner, MD, PhD
Pfützner Science and Health Institute, Mainz, Germany
10:25
Irl Hirsch, MD
University of Washington School of Medicine, Seattle, Washington, USA
10:35
11:00
Session 3: What Are Recent Developments in Regulatory Science for Diabetes Devices?
11:25
Alberto Gutierrez, PhD
NDA Partners, LLC, Rochelle, Virginia, USA
Yarmela Pavlovic, JD
Manatt Health, San Francisco, California, USA
11:35
Naomi Schwartz, MS
FDA, Silver Spring, Maryland, USA
11:45
Yiduo Wu, PhD
FDA, Silver Spring, Maryland, USA
11:55
Suzanne Schwartz, MD, MBA
FDA, Silver Spring, Maryland, USA
12:05
Ken Quinto, MD, MPH
FDA, Silver Spring, Maryland, USA
12:15
12:40
Session 4: What Is the Role of Pharma in Digital Health?
13:35
Juan Espinoza, MD, FAAP
University of Southern California, Los Angeles, California, USA
Matthew Taylor, CFA
MedTech Supplies & Devices Analyst, UBS-ARC, New York, New York, USA
13:40
David Kerr, MBChB, DM, FRCP, FRCPE
Sansum Diabetes Research Institute, Santa Barbara, California, USA
13:50
Howard Wolpert, MD
Lilly Cambridge Innovation Center, Cambridge, Massachusetts, USA
14:00
Anders Toft, MD, PhD, eMBA
Novo Nordisk, Copenhagen, Denmark
14:10
Christopher Boulton, BSc
Sanofi, Bridgewater, New Jersey, USA
14:20
Sam Collaudin, PhD, jMBA
Quarterly R&D Diabetes News Report, Marburg, Germany
14:30
Session 5: Artificial Pancreas (What Do Patients Like and Dislike About Their Automated Insulin Delivery Systems?)
15:05
Bruce Buckingham, MD
Stanford University, Palo Alto, California, USA
Alexander Fleming, MD
Kinexum Services LLC, Harpers Ferry, West Virginia, USA
15:10
15:30
Saturday, November 14, 2020
Session 6: Can We Build a Fully Automated AP Without Pre-Meal Announcements?
15:50
Jeffrey Joseph, DO
Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Laurel Messer, PhD, RN, CDCES
Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, USA
15:55
Marc Breton, PhD
University of Virginia, Charlottesville, Virginia, USA
16:07
Ali Cinar, PhD
Illinois Institute of Technology, Chicago, Illinois, USA
16:19
Roman Hovorka, PhD, FMedSci
University of Cambridge, Cambridge, UK
16:31
Frank Doyle, PhD, CPGS
Dean, Harvard John A. Paulson School of Engineering & Applied Sciences,
Cambridge, Massachusetts, USA
16:43
17:00
Session 7: What Is the Role of Ultra Short Acting and Ultra Long Acting Analog Insulins?
7:50
Gerold Grodsky, PhD
UCSF, San Francisco, California, USA
Tim Heise, MD
Profil, Neuss, Germany
8:05
Anne Peters, MD, FACP, CDE
University of Southern California, Los Angeles, California, USA
8:15
Athena Philis-Tsimikas, MD
Scripps Whittier Institute for Diabetes, UC San Diego, San Diego, California, USA
8:25
Leslie Klaff, MD, PhD
Rainier Clinical Research, Renton, Washington, USA
8:35
Bruce Bode, MD
Atlanta Diabetes Associates, Atlanta, Georgia, USA
8:45
Eda Cengiz, MD, FAAP, MHS
Yale University School of Medicine, New Haven, Connecticut, USA
8:55
Julio Rosenstock, MD
Dallas Diabetes and Endocrine Center, Dallas, Texas, USA
9:05
9:20
Session 8: How Should the Performance of CGM Systems Be Evaluated?
9:20
Craig Kollman, PhD
Jaeb Center for Health Research, Tampa, Florida, USA
Carlos Mendez, MD, FACP
Medical College of Wisconsin, Milwaukee, Wisconsin, USA
9:25
Tim Bailey, MD, FACE, FACP, CPI
AMCR Institute, Escondido, California, USA
9:40
David Horwitz, MD, PhD
DLH Biomedical Consulting LLC, Las Vegas, Nevada, USA
9:55
Guido Freckmann, MD
Institute for Diabetes Technology GmbH, Ulm, Germany
10:10
Rodolfo Galindo, MD, FACE
Emory University School of Medicine, Atlanta, Georgia, USA
10:25
David Kleidermacher, BS
Google, Mountain View, California, USA
10:40
10:55
Session 9: Is Digital Health Discriminatory?
11:20
Andrew Bremer, MD, PhD
NIDDK/National Institutes of Health, Bethesda, Maryland, USA
Sarah Kim, MD
UCSF, San Francisco, California, USA
11:20
Fazlyn Petersen, PhD
University of Western Cape, Cape Town, South Africa
11:30
Karl Friedl, PhD, COL
USAMRMC/Telemedicine and Advanced Tech Research Center, Fort Detrick, Maryland, USA
11:40
Celeste Campos-Castillo, PhD
University of Wisconsin Milwaukee, Milwaukee, Wisconsin, USA
11:50
Keesha Perkins-Crosby, MS
Tri-Guard Risk Solutions, LTD, Arlington, Virginia, USA
12:00
Elizabeth Burner, MD, MPH
University of Southern California, Los Angeles, California, USA
12:10
12:25
Session 10: Does Real Time Diabetes Monitoring Require More Metrics Than Glucose?
13:20
Avner Gal, MBA, MSCEE, MSc
Iridium Consultancy and Technologies, Ltd., Herzliya, Israel
Barry Ginsberg, MD, PhD
Diabetes Technology Consultants, Wyckoff, New Jersey, USA
13:25
Hope Warshaw, MMSc, RD, CDCES, BC-ADM
Hope Warshaw Associates, Alexandria, Virginia, USA
13:35
Dessi Zaharieva, PhD
Stanford University, Palo Alto, California, USA
13:45
Christian Cerrada, PhD
Evidation Health, Inc., San Mateo, California, USA
13:55
Jeffrey Joseph, DO
Thomas Jefferson University, Philadelphia, Pennsylvania, USA
14:05
Bijan Najafi, PhD
Baylor College of Medicine, Houston, Texas, USA
14:15
14:30
Session 11: Can Glucose Monitoring Predict the Future?
14:50
Thanh Hoang, DO
Walter Reed National Military Medical Center, Bethesda, Maryland, USA
Umesh Masharani, MD
UCSF, San Francisco, California, USA
14:55
Chiara Fabris, PhD
University of Virginia, Charlottesville, Virginia, USA
15:05
Bastiaan de Galan, MD, PhD
Maastricht University Medical Centre, Maastricht, Netherlands
Radboud University Medical Centre, Nijmegen, Netherlands
15:15
Pratik Choudhary, MBBD, MRCP, MD
University of Leicester, Leicester, UK
15:25
Dan Goldner, PhD
One Drop, New York, New York, USA
15:35
Pratik Agrawal, MS
Medtronic Diabetes, Northridge, California, USA
15:45
Jordan Messler, MD, SFHM, FACP
Glytec, Largo, Florida, USA
15:55
16:10
Live Demonstration
16:10
Rodolfo Galindo, MD, FACE
Emory University School of Medicine, Atlanta, Georgia, USA
Eun-Jung Rhee, MD, PhD
Kangbuk Samsung Hospital, Seoul, South Korea
16:15
Bijan Najafi, PhD
Baylor College of Medicine, Houston, Texas, USA
16:40
David Kerr, MBChB, DM, FRCP, FRCPE
Sansum Diabetes Research Institute, Santa Barbara, California, USA
16:45